Core Insights - iRhythm Holdings, Inc. presented new clinical evidence at the ACC 2026 Annual Scientific Sessions, reinforcing the effectiveness of its Zio ambulatory ECG monitoring service in identifying clinically relevant arrhythmias across diverse patient populations [1][6][14] Clinical Evidence - Two retrospective analyses highlighted the high prevalence of clinically actionable arrhythmias among patients with chronic kidney disease (CKD) and diabetes, indicating that these conditions significantly increase arrhythmia risk [3][4][7] - A study involving 657,147 individuals showed that 48% of patients with CKD and 47% of those with both diabetes and CKD experienced clinically actionable arrhythmias, compared to 39% of patients with diabetes alone and 35% without either condition [7] - Another analysis of 162,531 individuals found that higher body weight correlated with increased detection of atrial fibrillation (AF), with prevalence rising from 4.5% in normal/underweight patients to 6.5% in those with severe obesity [5][7] AI and Education Initiatives - iRhythm emphasized its leadership in AI within cardiology, with Chief Medical Officer Mintu Turakhia delivering a keynote on integrating AI into clinical practice [2][10] - The launch of iRhythm Academy aims to enhance clinician education on ambulatory cardiac monitoring, providing interactive courses and resources to improve patient care [2][13] Market Opportunity - With an estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias annually, iRhythm is focused on proactive cardiac monitoring and has partnered with Lucem Health to utilize predictive AI for identifying high-risk patients [9][10] - Data from previous studies indicated that arrhythmias often precede major health issues, highlighting the potential for earlier detection and intervention through iRhythm's monitoring solutions [8][9]